CAR-T cell therapy — engineering a patient's own immune cells to recognize and kill cancer — has transformed treatment of some blood cancers. But it has largely failed against solid tumors, which resist immune infiltration, suppress T cell function, and present antigen heterogeneity that allows escape. A Phase 1 clinical trial published this week reports complete remission in four of nine patients with metastatic colorectal cancer using a next-generation CAR-T construct that addresses all three of those barriers simultaneously. The sample size is small. The data is compelling.